The company said, “Pulmonx continues to expect revenue for the full year 2024 to be in the range of $81 million to $84 million. The Company continues to expect gross margin for the full year 2024 to fall within the range of 74% to 75%. Pulmonx continues to expect total operating expenses for the full year 2024 to fall within the range of $127 million to $129 million, inclusive of approximately $25 million of non-cash stock-based compensation.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LUNG:
- Pulmonx Reports Second Quarter 2024 Financial Results
- Pulmonx to Present at the Canaccord Genuity 44th Annual Growth Conference
- Pulmonx to Report Second Quarter 2024 Financial Results on July 31, 2024
- Lake Street highlights five ‘bargain bin’ small cap healthcare ideas for 2H
- Pulmonx initiated with a Buy at Lake Street